Overview

Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Treatments:
Antibodies, Monoclonal
Cetuximab
Irinotecan
Zalutumumab